ライフサイエンスコーパス: asymmetric dimethylarginine

1 s of high-sensitivity C-reactive protein and asymmetric dimethylarginine).

2 Asymmetric dimethylarginine (10 microM) or native low-de

3 Asymmetric dimethylarginine (ADMA) and homocysteine are

4 Asymmetric dimethylarginine (ADMA) and monomethyl argini

5 The endogenous methylarginines, asymmetric dimethylarginine (ADMA) and N (G)-monomethyl-

6 uanidino-methylated arginines (MA) including asymmetric dimethylarginine (ADMA) and N(G)-methyl-l-arg

7 The endogenous methylarginines asymmetric dimethylarginine (ADMA) and N(G)-monomethyl-L

8 The NOS inhibitors asymmetric dimethylarginine (ADMA) and N-monomethylargin

9 anidinomethylated arginines (MAs), including asymmetric dimethylarginine (ADMA) and NG-methyl-L-argin

10 r (15)N-arginine intravenous infusion and on asymmetric dimethylarginine (ADMA) and symmetric dimethy

11 n mammalian cells: monomethylarginine (MMA), asymmetric dimethylarginine (ADMA) and symmetric dimethy

12 Increased levels of asymmetric dimethylarginine (ADMA) are associated with e

13 oth fibroblast growth factor 23 (FGF-23) and asymmetric dimethylarginine (ADMA) are associated with p

14 The endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) circulates in plasma,

15 Elevated levels of asymmetric dimethylarginine (ADMA) correlate with risk f

16 We sought to determine if a reduction in asymmetric dimethylarginine (ADMA) enhances endothelial

17 ncentrations of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) in the hypoxia-induce

18 We have recently demonstrated that asymmetric dimethylarginine (ADMA) induces the transloca

19 We sought to determine whether asymmetric dimethylarginine (ADMA) inhibits nitric oxide

20 Asymmetric dimethylarginine (ADMA) is an endogenous comp

21 Asymmetric dimethylarginine (ADMA) is an endogenous inhi

22 Asymmetric dimethylarginine (ADMA) is an endogenous inhi

23 Asymmetric dimethylarginine (ADMA) is an endogenous meta

24 decreased, and the inhibitor of NO synthesis asymmetric dimethylarginine (ADMA) is increased.

25 The impact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been c

26 ne, and the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) were measured with li

27 ork implicating the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA), a cardiotoxic hormon

28 DDAH1 is a key catabolic enzyme of asymmetric dimethylarginine (ADMA), a major endogenous n

29 Both asymmetric dimethylarginine (ADMA), an endogenous inhibi

30 Asymmetric dimethylarginine (ADMA), an endogenous inhibi

31 Elevated blood concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibi

32 rogens regulate the metabolism or release of asymmetric dimethylarginine (ADMA), an endogenous inhibi

33 ffects in part by elevating plasma levels of asymmetric dimethylarginine (ADMA), an endogenous inhibi

34 dy prospectively determined plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric

35 l contributor to endothelial pathobiology is asymmetric dimethylarginine (ADMA), an endogenous nitric

36 Asymmetric dimethylarginine (ADMA), an endogenous nitric

37 Increased levels of asymmetric dimethylarginine (ADMA), an endogenous nitric

38 l contributor to endothelial pathobiology is asymmetric dimethylarginine (ADMA), an endogenous NO syn

39 AT) and assessed associations with arginine, asymmetric dimethylarginine (ADMA), and hemolysis.

40 aw the next morning for soluble CD40 ligand, asymmetric dimethylarginine (ADMA), and nitrotyrosine le

41 1) strictly generates monomethylarginine and asymmetric dimethylarginine (ADMA), but not symmetric di

42 risk factors, total homocysteine (tHcy) and asymmetric dimethylarginine (ADMA), correlate with decre

43 Plasma was assayed for endothelin 1 (ET-1), asymmetric dimethylarginine (ADMA), intercellular adhesi

44 dogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), is elevated in patie

45 a levels of arginine, citrulline, ornithine, asymmetric dimethylarginine (ADMA), symmetric dimethylar

46 function and raised plasma concentrations of asymmetric dimethylarginine (ADMA), the endogenous inhib

47 Asymmetric dimethylarginine (ADMA), which inhibits NO sy

48 e endogenous nitric-oxide synthase inhibitor asymmetric dimethylarginine (ADMA).

49 systemic levels of l-arginine and increased asymmetric dimethylarginine (ADMA).

50 nverts TbPRMT7 into a type I PRMT, producing asymmetric dimethylarginine (ADMA).

51 genous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA).

52 onist of NO synthase has been characterized: asymmetric dimethylarginine (ADMA).

53 We focused on asymmetric dimethylarginine (ADMA, the endogenous inhibi

54 CS patients had higher levels of asymmetric dimethylarginine (ADMA; P<0.0001), symmetric

55 Asymmetric-dimethylarginine (ADMA) limits NO production

56 e endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine [ADMA, via inhibition of dim

57 bin [TAT] complex), endothelial dysfunction (asymmetric dimethylarginine [ADMA]), and platelet-derive

58 Asymmetric dimethylarginine also stimulated MCP-1 format

59 vels of apolipoprotein AI and high levels of asymmetric dimethylarginine, an endogenous inhibitor of

60 lammation (C-reactive protein), or levels of asymmetric dimethylarginine, an endogenous inhibitor of

61 would be expected to lead to accumulation of asymmetric dimethylarginine and inhibition of NOS.

62 that 3.7% of the molecules naturally contain asymmetric dimethylarginine and/or monomethylarginine.

63 Decompartmentalized hemoglobin, arginase 1, asymmetric dimethylarginine, and adenine nucleotides are

64 1(-/-) mice showed a significant increase of asymmetric dimethylarginine concentration in plasma (1.4

65 Asymmetric dimethylarginine increases endothelial oxidat

66 Asymmetric dimethylarginine-induced monocyte binding was

67 Asymmetric dimethylarginine is an endogenous inhibitor o

68 Asymmetric dimethylarginine is eliminated largely by the

69 vascular cell adhesion molecule (VCAM), and asymmetric dimethylarginine levels were measured.

70 Asymmetric dimethylarginine may be an endogenous proathe

71 Asymmetric dimethylarginine plays a role in endothelial

72 eduction in the level of p-cresol sulfate or asymmetric dimethylarginine to significant reductions in

73 ype II activity) as well as small amounts of asymmetric dimethylarginine (type I activity).

74 uremic milieu contains increased amounts of asymmetric dimethylarginine, we speculate that such accu

75 stable nitric oxide oxidation products, and asymmetric dimethylarginine were abnormal in patients wi

76 plasma levels of l-arginine, arginase-1, and asymmetric dimethylarginine were measured at serial time

77 vely small amounts of monomethylarginine and asymmetric dimethylarginine were produced.

78 il, betaine, symmetric dimethylarginine, and asymmetric-dimethylarginine), were also increased in uri